KEYNOTE 021G

After the close on Wednesday, Merck & Co., Inc. (NYSE: MRK) announced that the FDA had accepted its filing for Keytruda based on the KEYNOTE 021G data presented by the company at ESMO comparing the drug candidate plus chemo to chemo alone in 1L lung cancer. Piper Jaffray’s Richard J....